Convergence's CNV1014802 meets in trigeminal neuralgia

Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) said thrice-daily CNV1014802 met the primary endpoint of improving the rate of treatment failure vs. placebo in the double-blind portion of a Phase IIa trial to treat pain associated with trigeminal neuralgia (33% vs. 65%). Treatment failure was defined as a 50% increase in the frequency of paroxysms -- or sudden worsening or recurrence of the disease or symptoms -- or severity of pain of paroxysms compared to the final seven days of the open-label treatment period, a patient's rating of "much worse" or "very much worse" or discontinuation due to lack of efficacy or adverse events. Data will be presented at the International Association for the Study of Pain meeting in October. ...